IS6891A - Aðferðir við gjöf epóþílon hliðstæðna við meðferðkrabbameins - Google Patents

Aðferðir við gjöf epóþílon hliðstæðna við meðferðkrabbameins

Info

Publication number
IS6891A
IS6891A IS6891A IS6891A IS6891A IS 6891 A IS6891 A IS 6891A IS 6891 A IS6891 A IS 6891A IS 6891 A IS6891 A IS 6891A IS 6891 A IS6891 A IS 6891A
Authority
IS
Iceland
Prior art keywords
methods
treatment cancer
epothilone analogues
administering epothilone
administering
Prior art date
Application number
IS6891A
Other languages
English (en)
Other versions
IS2865B (is
Inventor
Bandyopadhyay Rebanta
M. Malloy Timothy
Panaggio Andrea
Srinivas Raghavan Krishnaswamy
Amilal Varia Sailesh
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28678063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS6891(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2002/001813 external-priority patent/WO2002058700A1/en
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of IS6891A publication Critical patent/IS6891A/is
Publication of IS2865B publication Critical patent/IS2865B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IS6891A 2001-01-25 2003-07-24 Aðferðir til þess að tilreiða lyfjablöndur, sem innihalda epóþílónhliðstæður, til þess að meðhöndla krabbamein IS2865B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26422801P 2001-01-25 2001-01-25
US29000801P 2001-05-11 2001-05-11
PCT/US2002/001813 WO2002058700A1 (en) 2001-01-25 2002-01-22 Methods of administering epothilone analogs for the treatment of cancer

Publications (2)

Publication Number Publication Date
IS6891A true IS6891A (is) 2003-07-24
IS2865B IS2865B (is) 2014-02-15

Family

ID=28678063

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6891A IS2865B (is) 2001-01-25 2003-07-24 Aðferðir til þess að tilreiða lyfjablöndur, sem innihalda epóþílónhliðstæður, til þess að meðhöndla krabbamein

Country Status (24)

Country Link
US (1) US6670384B2 (is)
EP (2) EP1353668B1 (is)
KR (1) KR100851719B1 (is)
CN (1) CN100341505C (is)
AR (1) AR032409A1 (is)
AT (1) ATE389401T1 (is)
BG (1) BG66494B1 (is)
BR (1) BRPI0206509B8 (is)
CY (1) CY1108114T1 (is)
CZ (1) CZ20032021A3 (is)
DE (1) DE60225666T2 (is)
DK (1) DK1353668T3 (is)
EE (1) EE05301B1 (is)
ES (1) ES2304240T3 (is)
HU (1) HU229349B1 (is)
IS (1) IS2865B (is)
NO (1) NO20130070L (is)
NZ (1) NZ526870A (is)
PE (1) PE20020734A1 (is)
PT (1) PT1353668E (is)
SK (1) SK288098B6 (is)
TW (1) TWI342211B (is)
UY (1) UY27137A1 (is)
YU (1) YU58203A (is)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6242469B1 (en) 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
EP1353667A1 (en) * 2001-01-25 2003-10-22 Bristol-Myers Squibb Company Parenteral formulations containing epothilone analogs
WO2002066038A1 (en) 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives
CA2440555A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
WO2003077903A1 (en) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO2004018478A2 (en) 2002-08-23 2004-03-04 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20060235059A1 (en) * 2003-09-02 2006-10-19 Dilea Clifford Cancer treatment with epothilones
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
MX2007005763A (es) * 2004-11-18 2007-07-20 Squibb Bristol Myers Co Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma.
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
EP1674098A1 (en) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
JP2008536479A (ja) 2005-02-11 2008-09-11 ユニバーシティ オブ サザン カリフォルニア ジスルフィド架橋を有するタンパク質の発現法
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US8008256B2 (en) 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
CN103037903A (zh) 2010-05-18 2013-04-10 天蓝制药公司 用于治疗自身免疫性疾病或其它疾病的组合物和方法
CA2838387A1 (en) 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
PL401116A1 (pl) * 2012-10-09 2014-04-14 Ryszka Florian Farmaceutyczny Zakład Naukowo-Produkcyjny Biochefa Kompozycja dodawana do płynów infuzyjnych
CN107041886A (zh) * 2016-02-06 2017-08-15 北京华昊中天生物技术有限公司 脱环氧埃坡霉素衍生物制剂、制备及其治疗肿瘤的应用
BR112022013685A2 (pt) 2020-01-10 2022-09-06 R Pharm Us Operating Llc Composições de ixabepilona
JP7536098B2 (ja) * 2020-09-02 2024-08-19 北京華昊中天生物医薬股▲ふん▼有限公司 ウチデロンの経口固形製剤

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
ATE218556T1 (de) 1995-11-17 2002-06-15 Biotechnolog Forschung Gmbh Epothilon-derivate und deren herstellung
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
JP4274583B2 (ja) 1996-11-18 2009-06-10 ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） エポチロンｃ，ｄ，ｅ及びｆ、製造と薬剤
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6242469B1 (en) * 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
EP1201666A3 (de) 1997-02-25 2003-03-05 Gesellschaft für biotechnologische Forschung mbH (GBF) Seitenkettenmodifizierte Epothilone
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
EP0975622B1 (de) 1997-04-18 2002-10-09 Studiengesellschaft Kohle mbH Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ES2184307T3 (es) 1997-07-16 2003-04-01 Schering Ag Derivados de tiazol, procedimiento para su preparacion y su utilizacion.
CA2299608A1 (en) 1997-08-09 1999-02-18 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
MY125921A (en) 1998-02-05 2006-08-30 Novartis Ag Compositions containing organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
JP2002504540A (ja) 1998-02-25 2002-02-12 スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ エポチロンの合成、その中間体およびそのアナログ
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
WO2000000485A1 (de) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
KR100851418B1 (ko) 1998-11-20 2008-08-08 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
AU2795000A (en) * 1998-12-22 2000-07-12 Novartis Ag Epothilone derivatives and their use as antitumor agents
NZ513268A (en) 1999-02-18 2004-05-28 Schering Ag 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
PE20010116A1 (es) 1999-04-30 2001-02-15 Schering Ag Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion
WO2001092255A2 (en) * 2000-05-26 2001-12-06 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same

Also Published As

Publication number Publication date
BG108112A (bg) 2004-11-30
BRPI0206509B8 (pt) 2021-05-25
YU58203A (sh) 2006-08-17
UY27137A1 (es) 2002-08-30
HUP0302726A3 (en) 2007-08-28
CN100341505C (zh) 2007-10-10
HUP0302726A2 (hu) 2003-11-28
DE60225666D1 (de) 2008-04-30
AR032409A1 (es) 2003-11-05
EE05301B1 (et) 2010-06-15
US6670384B2 (en) 2003-12-30
DE60225666T2 (de) 2009-04-16
KR100851719B1 (ko) 2008-08-11
ES2304240T3 (es) 2008-10-01
BG66494B1 (bg) 2015-06-30
SK8562003A3 (en) 2004-07-07
PE20020734A1 (es) 2002-08-17
SK288098B6 (sk) 2013-07-02
HK1065946A1 (en) 2005-03-11
EE200300320A (et) 2003-10-15
EP1353668A1 (en) 2003-10-22
TWI342211B (en) 2011-05-21
DK1353668T3 (da) 2008-06-30
CN1496258A (zh) 2004-05-12
EP1938821A2 (en) 2008-07-02
EP1938821A3 (en) 2009-02-18
CZ20032021A3 (cs) 2004-05-12
BRPI0206509A8 (pt) 2017-09-19
HU229349B1 (en) 2013-11-28
EP1353668B1 (en) 2008-03-19
HK1116339A1 (en) 2008-12-19
NO20130070L (no) 2003-09-04
ATE389401T1 (de) 2008-04-15
US20020169190A1 (en) 2002-11-14
PT1353668E (pt) 2008-06-30
EP1938821B1 (en) 2016-03-30
BRPI0206509B1 (pt) 2018-10-02
BR0206509A (pt) 2004-09-08
KR20040048874A (ko) 2004-06-10
NZ526870A (en) 2005-11-25
CY1108114T1 (el) 2014-02-12
IS2865B (is) 2014-02-15

Similar Documents

Publication Publication Date Title
CY2019030I1 (el) Παραγωγο ραπαμυκινης για την θεραπευτικη αντιμετωπιση του καρκινου του πνευμονα
ZA200305126B (en) Methods of administering epothilone analogs for the treatment of cancer.
CY2015003I1 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
EP1535610A4 (en) THERAPEUTIC CANCER
NO20035156L (no) Fremgangsmåter for brønnbehandling
DE60138611D1 (de) Synergistische kombinationstherapie zur krebsbehandlung
NO20052914D0 (no) Terapeutiske forbindelser
DE60322451D1 (de) 4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung
IL224393B (en) Compositions for treatment of huntington's disease
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
EE200200571A (et) Hüdroksüfenüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks
CY2018006I2 (el) Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
IS6917A (is) Epóþílon afleiður til meðhöndlunar erfiðra æxla
NO20033205D0 (no) Terapeutiske kromanforbindelser
DE60223576D1 (de) Hautbehandlungszusammensetzung
IL160928A0 (en) Use of histamine to treat liver disease
EE200200511A (et) Hüdroksüfenüülpiperasinüülmetüülbensamiidi derivaadid valu raviks
DK1553950T3 (da) Terapeutisk behandling
EE200200577A (et) Kinolinüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks
NO20033341D0 (no) Metoder for administrering av epothilone-analoger for behandling av kreft
DE60222664D1 (de) Hautbehandlungsmittel
DE60329308D1 (de) Oberflächenbehandlung
DE60328516D1 (de) Thia-epothilon derivate zur krebsbehandlung
DK1618130T3 (da) Terapeutisk cancervaccine
NO20042850L (no) Kreftbehandling